CJC-1295 No DAC
GHRH-receptor agonist based on GHRH(1-29), supplied without the drug-affinity complex. The no-DAC form is the short-acting analog.
For laboratory research use only. Material is supplied as a research reference standard and is not approved by Health Canada. Protocols below are compiled from published literature and supplier documentation; they are reference information, not medical advice. Anyone with a health condition or on medication should speak to a physician first.
Before you begin
- • Lot-matched certificate and laboratory notebook
- • Calibrated pipettes, low-binding tubes and suitable PPE
- • Validated solvent, assay reagents and model-specific SOP
- • Appropriate positive, negative and vehicle controls
Required controls
- Vehicle-only negative control
- Receptor-null or antagonist condition
- Validated reference ligand
- Untreated viability control
Reported protocol
- Standard
- 100 mcg per injection, paired 1:1 with ipamorelin in the blend protocol
- Frequency
- 1 to 3 times daily (morning, post-workout, pre-bedtime)
- Fasting requirement
- Administer on an empty stomach: no food 2 h before, 30 min after
- Route
- Subcutaneous
Diluent
Sterile bacteriostatic water (0.9% benzyl alcohol) for multi-withdrawal stock, or sterile water for injection where a preservative-free stock is required by the assay.
Compound-specific: Confirm you are working with the no-DAC analog before comparing against any published result. A large part of the CJC-1295 literature uses the DAC-modified molecule and the kinetics are not comparable.
Reconstitution concentrations
Solvent volume sets the stock concentration. Lower volume gives a more concentrated stock and smaller working aliquots; higher volume gives a more dilute stock that is easier to measure accurately.
| Solvent added | Stock concentration | Per 0.1 mL | Per unit (U-100) |
|---|---|---|---|
| 1 mL | 10 mg/mL | 1 mg | 100 mcg |
| 2 mL | 5 mg/mL | 500 mcg | 50 mcg |
| 3 mL | 3.33 mg/mL | 333.33 mcg | 33.33 mcg |